Business Context and Reporting Period
Company: Contineum Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2026
Reporting Period: Single event date (September 14, 2026)
Contineum Therapeutics, Inc. is a Delaware corporation with its principal executive offices in San Diego, California. The company is listed on the Nasdaq Global Select Market under the symbol CTNM. This filing reports a material event regarding the clinical development of its licensed asset.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to reporting a specific corporate event and does not provide quantitative financial metrics for the period.
Material Changes
The material change reported is the announcement of results from the MOONLIGHT-1 Phase 2 clinical trial. Key details include:
- Asset: JNJ-5120/PIPE-307.
- Indication: Major depressive disorder (MDD) in adult participants.
- Study Design: Monotherapy evaluation of efficacy, safety, and tolerability.
- Partnership: Johnson & Johnson is developing the asset under a global license and development agreement with Contineum.
The filing text does not provide the specific numerical results or statistical outcomes of the trial, only that the results were reported in a press release.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) containing the full details of the trial results. No specific forward-looking guidance, financial outlook, or management commentary is included in the body of this 8-K text.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainty of clinical trial outcomes, which are standard for biopharmaceutical companies. The success or failure of the MOONLIGHT-1 trial represents a significant contingency for the company's pipeline value.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific efficacy and safety data of the MOONLIGHT-1 trial.
- Verify the impact of the trial results on the global license agreement with Johnson & Johnson, including potential milestone payments or royalty implications.
- Check subsequent filings (e.g., 10-Q or 10-K) for any financial impact resulting from this event.
- Confirm the regulatory next steps for JNJ-5120/PIPE-307 following the Phase 2 results.